Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epacadostat - Incyte Corporation

Drug Profile

Epacadostat - Incyte Corporation

Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 12 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer Aduro BioTech; Bristol-Myers Squibb; Columbia University; IMV; Incyte Corporation; MedImmune; Merck AG; Merck Sharp & Dohme; National Cancer Institute (USA); Sidney Kimmel Cancer Center; Stanford University
  • Class Antineoplastics; Oxadiazoles; Small molecules; Sulfonamides
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours
  • Phase I/II Cancer; Colorectal cancer; Glioblastoma; Prostate cancer

Most Recent Events

  • 01 Feb 2019 Incyte Corporation and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins initiate the Window of Opportunity phase I pharmacodynamics trial for Solid tumours (Resectable) in USA (PO) (NCT03471286)
  • 16 Oct 2018 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase I trial for Glioblastoma (Recurrent disease, Combination therapy, Second line therapy or greater) (IV) in November 2018 (NCT03707457)
  • 14 Sep 2018 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme withdraws a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) prior to enrolment in the USA (NCT03182894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top